Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Comparative Analysis of Gut Microbiome Profiles in Hepatocellular Carcinoma Patients Responding and Not Responding to Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis
Clinical Scorecard: Comparative Analysis of Gut Microbiome Profiles in Hepatocellular Carcinoma Patients Responding and Not Responding to Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Hepatocellular Carcinoma (HCC)
Key Mechanisms
Gut microbiota dysbiosis and its association with immune checkpoint inhibitor therapy response.
Target Population
Patients with intermediate-to-advanced HCC receiving immune checkpoint inhibitors.
Care Setting
Oncology and hepatology clinics.
Key Highlights
Beta diversity significantly differed in over 68% of studies.
Actinobacteriota enriched in responders; Bacteroides depleted in non-responders.
Protective taxa correlated with lower mortality risk include Collinsella and Ruminococcus.
Detrimental taxa associated with worse overall survival include Bacteroides.AF20_13LB and Veillonella atypica.
Distinct gut microbiome profiles may indicate disease status and treatment response.
Guideline-Based Recommendations
Diagnosis
Utilize gut microbiome profiles to assess treatment response in HCC patients.
Management
Consider gut microbiota composition when evaluating therapeutic strategies for HCC.
Monitoring & Follow-up
Monitor changes in gut microbiome as potential biomarkers for treatment efficacy.
Risks
Identify high-risk taxa that may predict poor outcomes in HCC patients undergoing ICI therapy.
Patient & Prescribing Data
Adults with intermediate and advanced hepatocellular carcinoma.
Immune checkpoint inhibitors may yield variable responses influenced by gut microbiome composition.
Clinical Best Practices
Incorporate gut microbiome analysis in clinical decision-making for HCC treatment.
Evaluate the role of gut microbiota in predicting patient outcomes during ICI therapy.
